When Is It Time to Switch From an FcRN?

Key Takeaways:

• Don't call it a failure too soon. Before switching, optimize the regimen – cycle frequency, timing, and route (particularly in relation to end-of-cycle wearing off or suboptimal trough coverage) – since individualized dosing rescues many apparent non-responders.
• Switch for the right reasons. True triggers are primary non-response despite IgG reduction, secondary loss of benefit, intolerability, or recurrent breakthrough disease – not fluctuating symptoms without objective treatment failure.
• Let antibody status guide the next step. Choose a complement inhibitor, another FcRn agent, or alternative immunotherapy based on AChR/MuSK status and the specific failure mode (mechanism of inadequate response is more important than drug class sequence alone).

Neonatal Fc receptor (FcRn) antagonists have reshaped the management of generalized myasthenia gravis (gMG), offering rapid, targeted reduction of pathogenic IgG without global B-cell depletion or complement blockade. In the ADAPT trial, 68 percent of acetylcholine receptor antibody-positive patients treated with efgartigimod were MG-ADL responders in the first cycle, compared with 30 percent on placebo. Rozanolixizumab produced similarly meaningful improvements in the MycarinG study.^1-3

Yet the same trials make clear that a substantial minority of patients respond inadequately, lose benefit over time, or struggle with the rhythm of cyclic dosing. For the treating clinician, the practical question is identifying true therapeutic non-response versus underdosing or cycling-related wearing-off. This article outlines a structured approach to that decision.

Define the target before judging the response

Switching treatment decisions should be based on clear clinical response criteria rather than subjective impression of improvement alone. The most widely used benchmark is the MG-ADL responder definition (a sustained improvement of at least 2 points), with minimal symptom expression (MG-ADL of 0-1) representing the more ambitious target now achievable in a meaningful proportion of patients.^1,4

Across trials, FcRn inhibitors reliably lower MG-ADL, QMG, and MGC scores with a consistent, predictable range of clinical response when dosing is adequate. If someone never gets there despite good IgG reduction and adequate exposure, that is when you start thinking about true non-response.^5,6

Optimize dosing before abandoning the drug

A frequent error is to label a patient a non-responder before the regimen has been optimized in practice (especially with cyclic FcRn therapies). FcRn inhibition was designed for flexible, response-driven dosing, and the interval between cycles is a powerful lever that should be titrated based on end-of-cycle symptom return and clinical wearing off.⁴

The ADAPT NXT study demonstrated that efgartigimod, administered either as fixed cycles or every other week, produced robust, sustained MG-ADL improvement, with minimal symptom expression reached by roughly 45 percent of patients across regimens.⁴

Similarly, open-label extension data show that chronic weekly rozanolixizumab maintained benefit across up to 52 infusions, without clear evidence of loss of effect over time, and subcutaneous efgartigimod proved noninferior to the intravenous formulation, expanding administration options.^5,7

Before concluding that an FcRn inhibitor has failed, clinicians should therefore confirm that cycle frequency, route, and timing have been adjusted to the patient's symptom pattern – and that end-of-cycle wearing off has been distinguished from true primary non-response.

Recognize genuine reasons to switch

Once dosing is optimized, several scenarios legitimately point toward a change in clinical practice. The first is primary inadequate response: a patient who never achieves a clinically meaningful MG-ADL improvement despite confirmed IgG reduction. Emerging mechanistic work helps explain this, showing heterogeneous immunologic responses to FcRn blockade and identifying transcriptional signatures in suboptimal responders, a reminder that IgG lowering does not uniformly translate into clinical benefit.⁸

The second is secondary loss of response, in which initial gains wane across successive cycles and cannot be recovered by shortening intervals, despite continued IgG suppression and adequate dosing. The third is intolerability or safety concerns – while FcRn inhibitors are generally well tolerated, recurrent infections or persistent adverse events may force reconsideration.⁶

Finally, breakthrough disease requiring frequent rescue therapy (IVIG or PLEX despite maintenance therapy) signals that the current strategy is insufficient, regardless of nominal responder status.

Choosing the next step

The destination depends heavily on antibody status and the reason for switching. For a patient who tolerated an FcRn inhibitor but responded inadequately, a complement inhibitor is a rational alternative in AChR-positive disease. Network meta-analysis suggests broadly comparable efficacy between the 2 classes, though FcRn agents showed a greater short-term effect on QMG scores.³

For MuSK-positive patients, complement inhibition is not appropriate, making a second FcRn agent or an alternative immunotherapy more relevant (as complement activity is not a dominant driver in this subtype). Notably, FcRn inhibitors are approved for both AChR- and MuSK-positive disease. Switching within the FcRn class may also be considered when the issue is tolerability or administration burden rather than mechanism.²

A disciplined assessment

Deciding when to switch from an FcRn inhibitor is fundamentally a matter of disciplined assessment and should be based on 3 core clinical questions:

• Define the response target explicitly.
• Exhaust individualized dosing options, including adjustment of interval and route based on wearing-off patterns.
• Reserve switching for true primary non-response, secondary loss of benefit, intolerability, or recurrent breakthrough disease requiring rescue therapy.

When a change is warranted, antibody status and the specific failure mode should guide whether the patient moves to a complement inhibitor, an alternative FcRn agent, or another immunotherapy rather than a predetermined class sequence. Applied consistently, this framework helps ensure that patients neither linger on an ineffective regimen nor abandon a treatment that simply needs refinement.